Fresh off the research radar — new HBOT science just published, summarized for our community.
Title:
Prospective registry finds 56–63% of long COVID patients show meaningful improvement 3 months after HBOT, especially in cognition
What this study examined
Long COVID has created a huge unmet need for treatments that improve:
- chronic fatigue
- brain fog
- cognitive dysfunction
- reduced physical capacity
- reduced quality of life
Clinical demand for HBOT has grown quickly, but formal guidelines are still lacking.
To better understand real-world outcomes, researchers established a prospective registry tracking long COVID patients undergoing HBOT.
This publication reports the 3-month results.
HBOT treatment details
The registry abstract does not specify exact treatment parameters, but the Netherlands long COVID programs typically use:
- 2.0 ATA
- 90 minutes
- with air breaks
- 30–40 sessions
These are standard neuroplasticity protocols.
Who was included?
Patients with long-term symptoms after COVID infection.
Patient-reported outcomes were collected:
- at baseline
- after HBOT
- at 3 months (this publication)
- with 1-year data coming later
Key findings at 3 months
1. 56–63% of patients had clinically meaningful improvement
A ≥10-point increase in physical or mental health scores on the SF-36 questionnaire was considered meaningful.
2. Cognitive symptoms improved the most
Patients commonly reported:
- clearer thinking
- reduced brain fog
- improved memory
- better concentration
3. 13–19% of patients worsened
A minority experienced clinically meaningful deterioration in their SF-36 scores.
This highlights the need for careful pacing and individualized protocols.
4. Secondary outcomes improved for many patients
Including:
- overall quality of life
- symptom burden
- ability to work
Why this matters
This is one of the largest real-world datasets for long COVID HBOT so far.
It shows a strong trend toward improvement — especially cognitively — but also makes it clear that not everyone tolerates standard protocols well.
Why some long COVID patients worsen — and why mild HBOT may be safer
Many long COVID patients have underlying:
- mitochondrial dysfunction
- dysautonomia
- neuroinflammation
- impaired redox balance
When pressures are too high (e.g., 2.0 ATA), oxidative stress can temporarily exceed the brain’s capacity to regulate it — leading to:
- symptom flares
- fatigue crashes
- neurological worsening
This matches the 13–19% deterioration seen in the registry.
This is exactly why Dr. Paul Harch recommends mild HBOT (typically 1.3-1.5 ATA) for cases involving:
- brain injury
- autonomic dysfunction
- chronic neurological inflammation
- long COVID and post-viral syndromes
According to Harch’s clinical experience and published work:
- mild pressures stimulate neuroplasticity with lower oxidative stress
- symptoms are less likely to flare
- improvements may come more gradually,
but the risk of worsening is dramatically reduced
For patients with fragile nervous systems — including long COVID — mild HBOT is often the safest and most stable entry point.
This aligns perfectly with the registry findings:
a notable minority worsened under higher-pressure protocols, while mild HBOT historically shows a much lower risk of adverse reactions.
Takeaway for the community
In this prospective registry:
- 56–63% of long COVID patients experienced meaningful improvement 3 months after HBOT
- cognitive improvement was the most pronounced
- 13–19% worsened — likely due to oxidative stress sensitivity and autonomic fragility
- this supports Dr. Harch’s recommendation to use mild HBOT for neurological and long COVID cases to reduce risk and improve tolerability
Mild HBOT may take longer, but it offers a safer, more sustainable path, especially for those with sensitive brains or unstable autonomic systems.
HBOT Radar continues to follow long COVID research and the emerging science guiding safer, more effective hyperbaric treatment strategies.
Study link: https://pubmed.ncbi.nlm.nih.gov/40759992/
